Hims & Hers Health (NYSE: HIMS) experienced an impressive 111% revenue surge in the first quarter, reaching $586 million, which contributed to an 18% increase in shares. Net income skyrocketed by 345% to $49 million, with a notable rise in new subscribers by 38%, totaling 2.4 million. The company is adapting its strategy for the long-term, projecting revenues of at least $6.5 billion by 2030. Despite the strong quarterly performance, the 2025 revenue guidance remained conservative. Hims has also partnered with Novo Nordisk to sell weight-loss drug Wegovy on its platform, broadening its service offerings.
Hims & Hers reported a remarkable 111% revenue increase to $586 million, driving its stock up 18%, alongside a 345% net income rise.
With a 38% surge in new members, reaching 2.4 million, Hims & Hers showcased a lucrative recurring revenue model through its telehealth platform.
Despite the robust Q1 growth, the full-year 2025 guidance remained conservative, indicating revenue estimates unchanged at $2.3-$2.4 billion.
Hims signed a partnership with Novo Nordisk to offer Wegovy on its platform, highlighting its push into the weight-loss drug market.
Collection
[
|
...
]